is feeling shroomy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the December 8 PR:
Widely recognized for its innovative portfolio of delivery methods, Mary's suite of cannabis products includes transdermal gels, patches, and topicals. Founded in 2013, the company possesses a robust library of intellectual property including a U.S. patent for its acclaimed transdermal technology. Dixie, a pioneer in the development of infused cannabis products since 2010, has built a robust stable of products including beverages, gummies, mints, and taffies. Dixie is the #1 edibles brand in the dynamic Michigan market (Source: Leaflink MarketScape, November 2020). Together, the BellRock brands offer one of the largest spectrums of high-quality consumer packaged goods in the cannabis industry with 11 brands and over 200 SKUs.
Once people catch on to the fact that Mary's holds the patent on Transdermal technology, this is game over.
Advantages of transdermal cannabis patches
Patches have long been used by the pharmaceutical industry to deliver compounds, including nicotine, estrogen, testosterone, the high-blood pressure medication clonidine, and the heart drug nitroglycerine. The mechanism is always the same: the patch is applied to the skin and the drug seeps into the bloodstream.
The direct-to-bloodstream path offers several advantages over other forms of cannabis consumption. For starters, delivery of the active ingredients is slow and steady. “With inhaling,” Riggle said, “you get a high dose right away, which your body metabolizes quickly. There's instant stimulation of the endocannabinoid system [ECS]. With slower, prolonged delivery, you can get the endocannabinoid system to where it's functioning optimally.”
Secondly, patches don't have the toxic byproducts of consumption methods such as smoking or vaping.
Transdermal patches also offer a key benefit over oral methods of consumption — tinctures, edibles, or sublingual sprays, strips, or drops. Consuming cannabis orally is what's known in pharmacology as “first-pass metabolism.” That means the active ingredient passes through your digestive system and then your liver before it reaches its intended destination; in the case of cannabis products, that's the ECS. As a result of that first pass, potency is greatly reduced. “If you orally consume 10 milligrams of THC or CBD, roughly half of that will be metabolized during a first pass,” Riggle said. Transdermal patches sidestep that dilution.
One final advantage: better control. “You can find out what dose works best for you,” Riggle said, “and then get the same precise dose every time
255000 shares just purchased 42% up from yesterday close.... what is happening here?
Full Story Here:
BellRock Brands Executes on Growth Strategy by Expanding into Florida via MedMen Partnership
BellRock Brands Inc.
Dec 17, 2020, 06:00 ET
MedMen stores across the state will begin carrying diverse line of Mary's and Dixie products in Q1 2021
DENVER, Dec. 17, 2020 /CNW/ - BellRock Brands Inc. ("BellRock" or "the Company") (CSE: BRCK.U), an industry-leading cannabis consumer packaged goods ("CPG") multi-state operator ("MSO"), announced today that the Company has entered into a licensing agreement with MedMen Enterprises Inc. ("MedMen") (CSE: MMEN) (OTCQX: MMNFF) to bring flagship brands, Mary's and Dixie, into MedMen stores across the state of Florida. MedMen, a leading cannabis retailer with operations across the United States, is now licensed to manufacture, distribute and sell Mary's Medicinals and Dixie products in their Florida retail locations.
Widely recognized for its innovative portfolio of delivery methods, Mary's suite of cannabis products includes transdermal gels, patches, and topicals. Founded in 2013, the company possesses a robust library of intellectual property including a U.S. patent for its acclaimed transdermal technology. Dixie, a pioneer in the development of infused cannabis products since 2010, has built a robust stable of products including beverages, gummies, mints, and taffies. Dixie is the #1 edibles brand in the dynamic Michigan market (Source: Leaflink MarketScape, November 2020). Together, the BellRock brands offer one of the largest spectrums of high-quality CPG products in the cannabis industry with 11 brands and over 200 SKUs.
"Florida represents an important market in our growth strategy, and we are very pleased to team up with MedMen to bring our flagship brands, Mary's and Dixie, into their stores and make our products available to residents in the state," said BellRock Brands Chief Executive Officer, Chuck Smith. "With the Florida market recently embracing infused products, we expect strong growth as the market continues to expand and the demand for diverse cannabis products increases."
BellRock expects to launch its initial products, including topicals, transdermal patches and gels, and ingestibles in Florida with MedMen during the first quarter of 2021, pending regulatory approval, with the balance of the portfolio coming on-line throughout the remainder of the year. The Company expects to begin distribution during Q1 across the entire MedMen retail platform, which includes four operational stores with plans to open in Miami Beach early in 2021.
"We are thrilled to have BellRock Brands join our product offering in Florida," said Tom Lynch, MedMen Interim Chief Executive Officer and Chairman of the Board. "Mary's and Dixie are two brands we hold in high regard, not only for their longstanding heritage in the cannabis industry, but also their focus on creating quality, trustworthy products that appeal to a wide range of cannabis consumers."
I loaded up today... Chart is looking tired of falling. ASX opened up 5% with 2.7mil volume in first 10 minutes of trading which is far more than anything we have seen lately. Also breaking out of channel it has been stuck in.
Loading zone
HUGE NEWS
Havn Life Sciences hits major milestone with research partner,
Complex Biotech Discovery Ventures
Havn Research signs contract with CBDV, located at The University of British Columbia’s Vancouver
campus, to begin Health Canada approved research to analyze psilocybin under Havn Life’s
Section 56 exemption.
The results of the analysis will allow Havn Life to begin the development of a library of psilocybin
compounds.
December 16, 2020
Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn
Life”), a biotechnology company pursuing standardized extraction of psychoactive
compounds, the development of natural healthcare products, and innovative mental health
treatment to support brain health and enhance the capabilities of the mind, is pleased to
announce it is partnering with Complex Biotech Discovery Ventures (CBDV) to begin Health
Canada approved analysis of psilocybin under Havn Life’s section 56 exemption.
CBDV is a licensed cannabis research and development firm focusing on extraction,
optimization, analytical testing and chemical process development based at the Vancouver
Campus at the University of British Columbia.
Havn Life will be conducting a comparative study at CBDV lab that will test various
methodologies of extraction to assess the merits and drawbacks of each. The results will be
used to help develop Havn Life’s methodology for analyzing psilocybin mushrooms and
products.
In addition, Havn Life will work towards the development of the very first library of psilocybin
compounds and lay the foundation for future development of proprietary extraction methods.
“Analysis is the foundation of Havn Life’s research objectives, enabling quality assurance and
rapid development of our extraction techniques and methodologies,” says Alexzander
Samuelsson, Chief Research Officer for Havn Life. “By building a foundational understanding
of current methods used today, we will leverage known research to develop an optimal process
for the standardization of psilocybin extraction. This ultimately allows Havn to supply academic
researchers with high quality, standardized compounds.”
The study will provide Havn Life with the tools and an understanding of method development
for specific compounds (psilocybin) that can later be used to develop a library of compounds
for researchers.
“It will also mean that Havn Life can rapidly develop our proprietary extraction methods in?house more quickly by eliminating the need to send compounds to third-party labs,” explains Samuelsson. “This makes a huge difference between discovery and optimization to scaling
processes, allowing Havn Life to expedite our internal development process.”
The work is enabled by Havn Life’s Section 56 exemption, granted by Health Canada, pursuant
to which the company has the ability to possess certain amounts of pure psilocybin for scientific
purposes, specifically for the research and development of quality control methods.
The Section 56 exemption also provides Havn Life with unique access to handle psilocybin and
develop in-house analytical protocols. This will provide experience in quantitatively analyzing
psilocybin as a cornerstone of quality control and quality assurance for process development
and product reliability
https://webfiles.thecse.com/Havn_NR_-_Dec_15_-_CBDV.pdf?vX7_Bn75CFlpXX7uw0vFmQXQB0ue6DXx
Added today at offering price. I believe this will follow a similar path that MindMed has had.
New Wave Enters Into Letter of Intent to Acquire Way of Will Inc. - A Leading Retailer of Aromatherpy Products Extracted From Natural Aromatic Plant Extracts and Essential Oils
/NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S. NEWSWIRES/
TORONTO, Dec. 15, 2020 /CNW/ - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTC: TRMNF) an investment issuer that provides capital and support services, is pleased to announce it has entered into a Letter of Intent (the "LOI") with Way of Will Inc. ("WoW") to acquire a 100% interest in the operations of WoW (the "Transaction"). WoW is a Canadian retailer of Aromatherapy products that use natural aromatic plant extracts and essential oils to promote healthy outcomes.
Way of Will Highlights
Founded in 2016, WoW is an aromatherapeutic essential oil-based wellness company based in Toronto, Canada. WoW products enhance your commitment to health, wellness and training by blending essential oils that protect, energize, refresh, relax, moisturize and groom the body and mind.
WoW manufactures ~95% of its products in it's Toronto based facility – sourcing the highest quality raw materials and packaging from key suppliers throughout Canada and other international markets.
WoW benefits from multi-channel sales (e.g. Wholesale, Retail and Ecommerce), which allows WoW to pivot their sales strategies based on changes in the sales landscape, as well as potential changes to the broader economy and marketplace dynamics
In-house manufacturing along with direct B2C sales through our ecommerce website platform allows WoW to control costs and optimize profit margins.
Growing US domiciled sales including 600+ retail and online ecommerce distribution channels.
Key retail clients include an impressive list of industry leading retailers such as Wholefoods, Target.com, FabFitFun, GNC, Dicks Sporting Goods and Causebox.
WoW products are also featured on popular ecommerce marketplaces such as Amazon and Walmart.com
Further information on WoW and its products can be found at https://www.wayofwill.com/
Gross sales are expected to be approximately $3.5 M for the year ended April 2021. Gross margins have historically been between 38% and 40%.
Terms of Transaction
Pursuant to the terms of the LOI and as consideration for the Transaction, the Company will issue $4,625,000 in common shares of the Company to the shareholders of WoW. The share price will be based on the 5-day VWAP leading up to the signing of a definitive agreement.
The parties intend to proceed to preparation of a definitive agreement and close the Transaction promptly and in accordance with the policies of the Canadian Securities Exchange (the "CSE"). The closing of the Transaction is subject to standard conditions precedent for transactions of a similar nature. There can be no assurance that the Transaction will be completed as proposed, or at all. The Transaction is an arms-length transaction and no change in management or the Board of Directors of New Wave is being contemplated at this time.
Daniel Fox, CEO New Wave Holdings Ltd. comments, "Way of Will is a natural fit for New Wave as we are both focused on broader natural health and wellness products. Way of Will's philosophy is based on natural wellness system rooted in essential oils and aromatherapy. I believe that aromatherapy is another powerful tool to promote long term human wellness and will also be an incredibly complimentary portfolio of products to our existing portfolio of CBD based and, functional mushroom blends that are at the core of New Wave's health and wellness product portfolio. I am also very impressed with the success of the Way of Will team in such a short-period time and am looking forward to finding a way for New Wave, N2 Logics and the Bloom Botanics e-commerce platform to accelerate WoW sales growth going forward. Our goal is to distribute and provide global consumers access to products that improve human functionality and performance. and we fully expect to continue to generate significant high margin growth in both North America and Europe."
We shall see. One of the only ways to play DMT right now. Up 50% from where I bought in originally.
New Wave: N2 Logics Acquires Bloom Botanics E-commerce Platform - One of Europe's Leading Nutraceuticals Online Superstore for CBD and Mushroom Blend Products
TORONTO, Dec. 14, 2020 /PRNewswire/ - N2 Logics Inc. in a joint venture with New Wave Holdings Ltd. – NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTC: TRMNF) an investment issuer that provides capital and support services, has announced that N2 Logics Inc. ("N2"), an entity that New Wave owns a significant interest in, has acquired one of Europe's leading CBD and nutraceuticals online superstore distributing various health & wellness products
Daniel Fox, CEO New Wave Holdings comments, "healthier and more natural plant based health and wellness products are continuing to grow in importance in today's society. Our goal is to distribute and provide consumers access to products that improve human functionality and performance. With N2's leading ecommerce strategy, we expect continue to generate significant high margin online growth starting in Europe then quickly expanding into North America and the rest of the world."
Bloom Botanics E-commerce platform is one of Europe's leading CBD online superstore and complex mushroom blends provider and looking to become a global leader in the mental health and wellness space. This is done by focusing on transparency and consumer education: specifically, using standardised measurements of strength and efficacy and being completely transparent about our CBD products and mushroom blends. Bloom Botanics is also committed to stocking only trustworthy lab-tested products which are fully compliant with "Novel Food" regulations.
The E-commerce strategy will be managed by N2 Logics Inc. N2's principals possess industry leading knowledge of nutraceuticals and have a proven track record of producing state of the art innovative E-commerce platforms and experiences. With their professionalism and passion, they understand the needs of consumers interested in natural health -boosting products.
With access to over 1,500 SKUs thanks to an exclusive dropship deal, Bloom Botanics has become Europe's consumers' go-to source for nutraceuticals and it's platform and ecommerce model will enable us to continue to expand it's already impressive portfolio of brand and wellness product offerings quickly and effectively.
Havn Life Sciences Undertakes One of the First Preclinical Studies on Psilocybin and the Immune System
December 14, 2020, 6:00 am
This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans
VANCOUVER, BC / ACCESSWIRE / December 14, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, is pleased to announce the first preclinical study to focus on the effects of psilocybin on the immune system, in partnership with Dr. Geoffrey Bove, Dr. David Mokler and Susan Chapelle, eMBA.
The Company's science division, Havn Research, is undertaking a study to determine if a single dose of psilocybin extract can impact the body's inflammatory response and regulate the human immune system.
The Havn Life team will begin this preclinical study in Q1 2021. This study is the first step required to file an application for the development of psilocybin delivery methods that could address inflammatory and immune diseases such as arthritis.
Vic Neufeld, Executive Chairman of Havn Life stated: "We are tremendously excited about the potential to accelerate drug discovery and patient access to psilocybin based compounds. Upon completion of this initial phase, the Havn Life team will have taken the first step on its journey towards market authorization of new medicines. We intend to pursue the filing of an FDA application for psilocybin-based delivery methods, which may ultimately lead to new drug discovery. To date, minimal research has been done on psilocybin and its effects on human immunity, which is an area that has become more and more important."
Although there is discussion related to the possible effects of psilocybin on inflammation, there has been no research on psilocybin's impact on the immune system. This will be the one of the first studies to quantify the effects of psilocybin on the immune system and will also compare the differences in how psilocybin affects the immune system between the sexes.
"This is an exciting new application for psilocybin that has not yet been researched. The work is essential to understanding the safety profile of psilocybin and developing medicines to help support human health," says Susan Chapelle. "The findings could lead to significant discoveries in the treatments of inflammatory diseases that have a profound negative effect on so many, such as pain, neuropathy and arthritis."
About the Study
The Havn Life study will be conducted in the United States at Dr. Bove's biomedical centre, in Maine.
The principal researchers will be Doctor Geoffrey Bove, Doctor David Mokler, and Susan Chapelle, EVP of Research and Development at Havn Life, who each have extensive clinical experience in wound healing, pain receptors, psychedelic and pharmacology research. They jointly published a research paper on post-operative adhesions in 2017. The study findings laid the groundwork for further research on mechanical and pharmacologic approaches for post-operative.
Doctor Mokler, is an advisor for Havn Life and has a dual doctorate Pharmacology/Toxicology and Neurosciences from Michigan State University. His research, funded by the National Institute of Mental Health, focuses on the limbic (emotion/behavior) system of the brain, and the role of serotonin in the limbic system.
Susan Chapelle, eMBA is an expert in wound healing and has co-authored 6 publications in peer reviewed journals. She is a noted international Keynote Speaker and industry expert on research, science education, urban transformation, cannabis and psychedelics policy, and technology integrations.
Geoffrey Bove, DC PhD is a career neurobiologist and chiropractor who researches pain mechanisms, especially as related to physical diagnosis and manual therapies. He has been independently funded by the National Institutes of Health and other institutions for 30 years. Previously faculty at Harvard Medical School, Dr. Bove conducts research at his private laboratory, Bove Consulting
Strong momo heading into EOD.. Next week should get real fun
Dips are opportunity.
Uplist* cannot happen until 5 consecutive CLOSES above $2. Today will be the 5th. The earliest possible uplist date would be Monday, but might take longer due to standard processing. I hope sometime next week, but it's coming either way.
Great move here. Once this gets noticed.....
Beautiful week here. Glad to be involved with this company
You almost never see companies run 20% on an offering completion date. Congrats everyone. Feels amazing to be involved with a company that is not only rewarding shareholders as heavily as this one has, but also doing amazing things for the world and mental health. Enjoy the weekend, everyone! And try not to check your portfolios every 5 minutes... just pinch yourself if you need a reminder if this is real life.
Volume in first 10 minutes higher than any daily volume ever. Getting noticed.
Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
https://www.otcmarkets.com/stock/MYCOF/news/story?e&id=1763078
New Wave Holdings Congratulates TheraPsil's Advocacy to Bring Psilocybin Therapy to Palliative Care for Canadian Patients
https://www.otcmarkets.com/stock/trmnf/news/story?e&id=1763424
Hollister Biosciences 100% Owned Subsidiary Venom Extracts Achieves Final $40 Million Revenue Milestone
https://www.otcmarkets.com/stock/hstrf/news/story?e&id=1763058
Beautiful shakeout event for those who held through the news and drop yesterday. This thing wants to fly.
Rules for uplisting... "The Fine Print"
https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5500-series#nasdaq-rule_5505
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Newsfile Corp.
December 9, 2020, 6:30 am
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances ("DMT") for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency (EMA) regulatory framework.
On November 27, 2020, Psygen successfully completed the production of a non-GMP DMT research batch for delivery to the Company's Contract Research Organization, CHDR's partner pharmacy. The non-GMP DMT research batch will be shipped to CHDR upon receipt of Psygen's export permit from the Health Canada Office of Controlled Substances. This export permit will be applied for following the successful receipt of CHDR's import permit, which has been applied for, and the granting of which is anticipated by the end of December.
The Agreement entered into on August 21, 2020 provides Entheon with access to a consistent DMT drug material for preliminary formulation, stability and testing required prior to its forthcoming human clinical trial, scheduled to begin in Q4 2021 at The Centre for Human Drug Research (CHDR) in the Netherlands.
"We are excited that Psygen has completed its initial research batch of non-GMP DMT. The completion of this batch represents the crucial chemical validation and formulation steps that are a regulatory requirement prior to human administration," said Chief Executive Officer of Entheon, Timothy Ko. "Partnering with Canada's first licensed manufacturer of restricted psychedelic drug products fosters an ecosystem of collaboration and innovation within the Canadian psychedelic space, and we are thrilled by the progress being made."
"We are excited to partner with Entheon Biomedical to supply DMT drug substance for its clinical research. We believe these studies will significantly improve outcomes for people who are suffering from substance use disorders," said Danny Motyka, CEO of Psygen.
Exercise of Warrants
Further, the Company is pleased to announce its shareholders have exercised an aggregate 533,359 warrants at a price of $0.75 per share and 13,334 warrants at $0.45 per share adding net proceeds of $406,019.55 to the Company's treasury. The warrants were issued by way of private placement with an expiry date of December 4, 2020. As of the expiry date, 82% of the warrants had been exercised. The use of proceeds will be employed to accelerate the Company's clinical and regulatory pathway. As of the date hereof, the Company has a total of 10,777,290 warrants that remain outstanding.
BellRock Brands Strengthens Presence in Nevada via Exclusive Licensing Agreement with Matrix NV
DENVER, Dec. 8, 2020 /CNW/ - BellRock Brands Inc. ("BellRock" or "the Company") (CSE: BRCK.U), an industry-leading cannabis consumer packaged goods ("CPG") multi-state operator ("MSO"), announced today that the Company has entered into a licensing agreement with Matrix NV, LLC (Matrix NV) to unify its award-winning Mary's and Dixie brands under one production and distribution partner in Nevada. Matrix NV, a Las Vegas, NV-based cannabis flower, concentrate and infused products producer, is now licensed to manufacture, distribute, and sell Mary's Medicinals and Dixie products to all cannabis retailers in the state. Those products include Mary's Medicinals Transdermal patches, Mary's Medicinals Transdermal gels, Mary's Medicinals Transdermal/topical compounds, Dixie gummies, Dixie mints and Dixie Elixirs.
Widely recognized for its innovative portfolio of delivery methods, Mary's suite of cannabis products includes transdermal gels, patches, and topicals. Founded in 2013, the company possesses a robust library of intellectual property including a U.S. patent for its acclaimed transdermal technology. Dixie, a pioneer in the development of infused cannabis products since 2010, has built a robust stable of products including beverages, gummies, mints, and taffies. Dixie is the #1 edibles brand in the dynamic Michigan market (Source: Leaflink MarketScape, November 2020). Together, the BellRock brands offer one of the largest spectrums of high-quality consumer packaged goods in the cannabis industry with 11 brands and over 200 SKUs.
"We are very pleased to partner with Matrix in Nevada and expand the presence of both Mary's and Dixie in the state," said Chuck Smith, Chief Executive Officer of BellRock. "This strategic partnership provides us with the opportunity to leverage our previous experience and operations in Nevada and bring a broader, more robust portfolio of BellRock products to this compelling market. As an experienced operator with a proven track record, Matrix is the perfect partner to help us introduce our iconic brands to more customers across the country and continue achieving our goal of building the first national cannabis brand."
BellRock expects to launch products in Nevada with Matrix NV during the first quarter of 2021. Retail sales of THC products across the state are estimated to exceed $780 million according to BDS Analytics.
"We have long admired both Mary's and Dixie for their commitment to providing cannabis consumers with quality, trustworthy products and their unique delivery methods. Their focus on producing a wide variety of superior products mirrors ours," said David Tuttleman, Chief Executive Officer of Matrix NV. "Adding these two established brands to our product portfolio is an exciting next step and we look forward to broadening their presence in Nevada and tapping the potential of the cannabis market in this state."
News out!! Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybin
DENVER, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has completed its first commercial harvest of 20 kilograms of psilocybin mushrooms at its research and cultivation facility in Jamaica. The Company is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealer’s License attached to it, allowing for legal import.
“We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms,” said Joshua Bartch, CEO and Chairman of Mydecine. “There is more research needed on these compounds in order to better understand the entourage effect experienced by patients which has shown dramatically effective results compared to single-molecule synthetic psilocybin in preliminary studies. As the industry grows, the need for naturally occurring psilocybin and access to large quantities of these molecules will be paramount and we are excited to be the first to advance this movement at scale.”
Once received by the Company’s facility in Canada, the psilocybin mushrooms will be extracted, refined and turned into a cGMP final product for controlled therapeutic purposes. Mydecine’s final product be made available for purchase by other licensed institutions and companies conducting clinical research into the efficacy of these compounds to treat various health conditions including anxiety, addiction, depression and PTSD. Portions of the harvest will also be used for Mydecine’s proprietary genetic, pharmacology, and clinical research. The clinical use will be for the studies and developing protocols of psilocybin-assisted psychotherapy to treat PTSD in veterans and other frontline workers.
https://www.otcmarkets.com/stock/MYCOF/news/story?e&id=1760660
New Wave: N2 Logics Launches New Website as They Explore Further Downstream Growth Opportunities
TORONTO, Dec. 7, 2020 /PRNewswire/ - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTC: TRMNF) an investment issuer that provides capital and support services, is pleased to announce its 50% owned digital marketing portfolio company N2 Logics Inc. ("N2"), has launched its own website N2logics.com as it considers incoming opportunities in the nutraceutical and functional mushroom space.
As set out in N2logics.com, N2 aims to refine the way digital growth is done by bringing a newer and leaner, cross-functional approach to marketing. The N2 philosophy removes the inefficiency of having a marketing team that has a developer, designers, SEO experts, PPC experts, content team and so on, by putting all the growth needs of any brand or site into small cross-functional agile teams. This joint venture with N2 provides New Wave with a leading edge in online growth strategy and the opportunities across the globe.
With over 25 years of digital growth experience between them and a proven track record of exponential online growth. The N2 team consists of some of the best minds in digital growth across the globe with multi award winning leadership for content, SEO and UX. First, Joshua Neilly, Ulster Bank Young Entrepreneur of the year 2019 who has worked with and tripled sales of brands such as Namaste and Herbalizestore. Working alongside Branislav Nikolic, who has been involved with successful growth periods of dozens of brands having worked with and grown Fourfivecbd, intertrade Ireland e-merge candidates, and herb.
N2 aims to provide insight to New Wave on existing portfolio brands while seeking out new, exciting and lucrative online opportunities. With a lean and data driven philosophy plus a great track record for success. N2 hopes to be launching its own initiatives by the end of Q1 2021.
Daniel Fox, CEO of New Wave comments, "Health and wellness is a theme of paramount importance in today's society and world. Our goal is to distribute and develop products that improve human functionality and performance. With our ecommerce strategy, we expect to potentially generate significant high margin online growth and N2 is uniquely positioned from a global standpoint to provide an industry leading edge experience to accomplish this".
https://www.otcmarkets.com/stock/TRMNF/news/story?e&id=1759193
Slacking on my duties ;) it's the weekend in Australia
Just need 5 days of $2 close price and all boxes should be checked for uplist.
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific").
Wonder Scientific's team of University Researchers and Product Development experts create custom, naturally derived, active pharmaceutical ingredients (APIs) to supply the growing global clinical and commercial demand for psychedelics.
Entheon's first strategic investment provides exposure in other verticals of the psychedelic therapy space and strategic access to psychoactive pharmaceutical ingredients and scientific bench strength as Entheon develops therapeutic treatments for addiction.
"Our investment in Wonder Scientific is part of our strategy in gaining low risk exposure to other segments of the regulated psychedelic treatment space," said Timothy Ko. "Their team of experienced pharmacologists and product experts enhances a strategic relationship providing opportunities for additional revenues from the company's line of genetics, bio-stimulants, and pharmaceuticals."
Tegan Adams, President & Founder of Wonder Scientific, commented on the partnership: "We are absolutely thrilled and privileged to have our value and strategy highlighted and recognized by Entheon management. We look forward to upcoming collaborations and a profitable symbiotic relationship."
Entheon is pleased to announce it has entered into an investor relations consulting agreement with Mr. Joseph Cullen.
Mr. Cullen's career has included over five years of public market experience, primarily focused on the resource and technology sectors with an emphasis on investor relations and corporate finance. His previous experience also includes working for Deloitte and VMWare, as well as co-founding and managing private ventures in the financial services, environmental consultancy, and technology sectors. Mr. Cullen is being paid $5000 per month for a one-year term.
Further, pursuant to its stock option plan, the Company has granted options to purchase up to 3,175,000 common shares in the Company (the "Options") to certain officers, directors and consultants of the Company. The Options are exercisable at $0.71 per share for a period of five years from the date of grant. Of the Options, 2,725,000 are subject to vesting over a 2-year term. The Options have been granted under and are governed by the terms of the Company's incentive stock option plan.
https://webfiles.thecse.com/sedar_filings/00043990/2012040533510240.pdf
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021
Vancouver, British Columbia–(Newsfile Corp. – December 1, 2020) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre for Human Drug Research (CHDR) to conduct an early phase human clinical trial with DMT.
CHDR is a Leiden, Netherlands-based contract research organization (CRO) that specializes in early-stage clinical drug research. Based on an agreement signed October 7th, 2020, Entheon has contracted CHDR to carry out a study to evaluate the pharmacodynamics, pharmacokinetics and safety of a target-controlled intravenous infusion of N,N-dimethyltryptamine (DMT) (the “Product”) in humans.
CHDR research director of psychiatry, Gabiel Jacobs stated, “The CHDR psychiatry team is looking forward to the exciting collaboration with Entheon in conducting this data-intensive study with DMT in humans. Characterization of both its functional central nervous system effects and its impact on subjective experience, and to relate these to its pharmacokinetics, is crucial to properly understand DMT’s potential as pharmacotherapeutic.”
“This is a significant milestone in our mission to develop therapeutic protocols to treat substance use disorders. We believe that the CHDR’s renowned expertise in conducting early-stage clinicals trials and their use of innovative technology makes them an excellent CRO to partner with,” said Timothy Ko, Chief Executive Officer of Entheon. “With the CHDR’s partner pharmacy having successfully received an amendment to its opiate license to include DMT and having applied for its import permit for DMT, we are advancing on steps for our clinical trial, which is expected to start in the late summer of 2021.”
https://webfiles.thecse.com/sedar_filings/00043990/2012010542166490.pdf
I was bored of seeing no movement to start the day and bid ask spread too far so I slapped for 100 shares... woke it up hahaha
Beauty
Took a starter on this one. Due for its rise from facility value and shroom boom.
Pullback was inevitable after going from .04s to .08s... healthy retracement and barely dipped below AUD price conversion. Good luck to all!